News
Tenaya Therapeutics
TNYA · NASDAQ
$0.41+$0.0324 (+8.58%)TodayMarket closed ·
Prev close $0.3776
Latest news
- Press releaseGlobe Newswire
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
- Press releaseGlobe Newswire
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- NewsVandana Singh
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
- Press releaseGlobe Newswire
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
- News
Earnings Scheduled For May 6, 2026
- Press releaseGlobe Newswire
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Press releaseGlobe Newswire
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
- NewsVandana Singh
Tenaya Therapeutics Stock Jumps After New Alnylam Deal
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
- NewsVandana Singh
Tenaya Stock Plunges After $60 Million Equity Offering
- NewsAvi Kapoor
S&P 500 Down 1%; Broadcom Earnings Top Views
- NewsAvi Kapoor
Dow Rises Over 100 Points; Lululemon Posts Upbeat Q3 Earnings
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- NewsVishaal Sanjay
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
- NewsRishabh Mishra
US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert
- NewsAvi Kapoor
Crude Oil Down Over 1%; US Industrial Production Declines In November
- NewsAvi Kapoor
Dow Dips Over 200 Points; US Retail Sales Top Estimates
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.